Abstract
Background: Patients with femoral head osteonecrosis usually tend to be younger and more active when compared with osteoarthritis patients. Second generation metal-on-metal THA was reintroduced to reduce poly-ethylene-induced wear debris, and therefore increase longevity of implants.
The aim of this retrospective study was to compare full blood cobalt-chrome levels, patient activity, clinical/radiological outcome and implant survival in patients with osteonecrosis and osteoarthritis after a minimum follow up of 12 years.
Methods: Full blood cobalt-chrome levels of a consecutive series of 125 patients, consisting of 40 patients (38 male, 2 female, average age 35 years, range 28 to 46 years) with osteonecrosis (ON group) and 85 patients (60 male, 25 female, average age 58 years, range 52 to 68 years) with osteoarthritis (OA group) as primary diagnosis were retrospectively compared. Patient activity level was assessed using UCLA Score and clinical outcome was evaluated using HHS. Radiological outcome and implant survival (Kaplan Meyer analysis) was determined in both groups.
Results: Patients with osteonecrosis of the femoral head showed significant higher UCLA scores when compared to OA group (4 versus 7) (p < 0.05). Despite this higher patient activity no significant difference was found between cobalt-chrome full blood levels (2.1/1.6 μg/l, ON group, 1.9/1.8 μg/l OA group, respectively) (p > 0.05). No positive correlation between patient activity, acetabular cup abduction angle and cobalt-chrome levels was found (r2 < 0.01). Clinical and radiological outcome were equal in both groups. Harris hip score was 91 points in the OA and 92 in the ON group (p > 0.05). Average cup inclination angle was 47° (range 32° to 55°) and 44° (range 30° to 56°) respectively (p > 0.05). Implant survival at 12 years follow up was 96% in the OA and 97% in the ON group.
Conclusion: After a minimum follow up of 12 years, we could not find increased metal levels in osteonecrosis patients when compared to the osteoartrithis group. Regarding our clinical and radiological outcome we cannot confirm previously published reports showing suboptimal results of THA in patients with osteonecrosis. Implant survival data did not differ among both group.
Metal on metal THA seems to be an effective and safe treatment option for these patients.
Correspondence should be addressed to: EFORT Central Office, Technoparkstrasse 1, CH – 8005 Zürich, Switzerland. Email: office@efort.org
